Trial Profile
A Phase 3, Randomized, Open Label Study Investigating the Efficacy of the BiTE Antibody Blinatumomab Versus Standard of Care Chemotherapy in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) (TOWER Study)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 15 Dec 2023
Price :
$35
*
At a glance
- Drugs Blinatumomab (Primary) ; Alkylating agents; Anthracyclines; Asparaginase; Clofarabine; Cytarabine; Etoposide; Fludarabine; Granulocyte colony-stimulating factors; Idarubicin; Methotrexate; Pegaspargase; Steroids; Vinca alkaloids
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms TOWER
- Sponsors Amgen
- 01 Nov 2023 Results published in the Cancer Immunology Immunotherapy
- 06 Oct 2023 Results of retrospective pooled analysis of 3 clinical trials( ZUMA-3, INO-VATE, and TOWER)estimating the relative treatment effects of brexu-cel versus inotuzumab ozogamicin (InO), blinatumomab (blina), and chemotherapies for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Adult Patients, published in the Advances in Therapy.
- 21 Jun 2023 According to an Amgen media release, based on additional data from two phase III trials, U.S. Food and Drug Administration (FDA) has approved supplemental Biologics License Application (sBLA) for BLINCYTO (blinatumomab) for the treatment of adults and pediatric patients with CD19-positive B-cell precursor acute lymphoblastic in first or second complete remission with minimal residual disease greater than or equal to 0.1%.